Fentanyl (Transdermal Patch)
Brand names: Durogesic DTrans, Matrifen, Fencino, Mezolar
This page covers transdermal fentanyl patches, a potent synthetic opioid delivery system for stable chronic severe pain in opioid-tolerant patients, not for acute or breakthrough pain.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
Fentanyl is a strong mu-opioid receptor agonist; the matrix or reservoir patch delivers it through the skin at a steady rate to maintain continuous plasma concentrations over several days.
Prescribing in practice
- Reserve for opioid-tolerant patients only, as initiating a patch in opioid-naive individuals risks fatal respiratory depression, and never apply to acute pain.
- Heat sources such as fever, hot baths, saunas and electric blankets accelerate absorption and can cause overdose, so warn patients to avoid them.
- Onset and offset are slow: a depot persists in the skin after removal, so monitor for delayed respiratory depression when stopping or switching.
Monitoring
Monitor pain control, sedation level and respiratory rate, especially after initiation, dose change or addition of other central nervous system depressants.
Counselling the patient
- Apply to clean, dry, non-irritated, hairless skin and rotate sites; do not cut the patch.
- Keep used and unused patches away from children and pets, and fold used patches in half before safe disposal as residual drug can be fatal.
- Avoid heat over the patch and report excessive drowsiness or slow breathing.
Evidence & guidelines
MHRA safety communications highlight risks of accidental exposure, heat-related overdose and use in opioid-naive patients, reinforcing the cautions in current prescribing references.
Reference: NICE NG31 (Cancer Pain); PCF6; Murtagh et al. Renal Palliative Care; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Morphine Milligram Equivalents (MME) Calculator · Pain / Opioids
- Opioid Conversion / Equianalgesic Guide · Pain Management
- Numeric Rating Scale (NRS) Pain Assessment and Management · Pain Management
- Finnegan Neonatal Abstinence Scoring Tool (FNAST) · Neonatal Abstinence Syndrome
- Modified Finnegan Neonatal Abstinence Score (NAS) · Neonatal
- Withdrawal Assessment Tool (WAT-1) for Paediatric Iatrogenic Withdrawal · Critical Care
- Sepsis Screening and Sepsis Six · UK Sepsis Trust; NICE NG51; Surviving Sepsis Campaign 2021
- Unintentional Weight Loss Workup · NICE NG12; BSG
- Chronic Fatigue Workup · NICE NG206; BMJ Best Practice
- Lymphadenopathy Workup · NICE NG12; BMJ Best Practice
- Pre-op Medical Clearance · NICE NG45; ESC 2022
- Secondary Hypertension Workup · NICE NG136; ESH 2023